JP2010500565A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010500565A5 JP2010500565A5 JP2009523844A JP2009523844A JP2010500565A5 JP 2010500565 A5 JP2010500565 A5 JP 2010500565A5 JP 2009523844 A JP2009523844 A JP 2009523844A JP 2009523844 A JP2009523844 A JP 2009523844A JP 2010500565 A5 JP2010500565 A5 JP 2010500565A5
- Authority
- JP
- Japan
- Prior art keywords
- markers
- expression
- level
- predictive
- marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003550 marker Substances 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 42
- 230000007774 longterm Effects 0.000 claims description 23
- 230000004083 survival effect Effects 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 238000011269 treatment regimen Methods 0.000 claims description 9
- 239000013610 patient sample Substances 0.000 claims description 8
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 6
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 4
- 229960001467 bortezomib Drugs 0.000 claims description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 239000003862 glucocorticoid Substances 0.000 claims description 4
- 239000003207 proteasome inhibitor Substances 0.000 claims description 4
- 239000000523 sample Substances 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 238000007619 statistical method Methods 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83676406P | 2006-08-10 | 2006-08-10 | |
| US60/836,764 | 2006-08-10 | ||
| PCT/US2007/017716 WO2008021183A2 (en) | 2006-08-10 | 2007-08-09 | For the identification, assessment, and treatment of patients with cancer therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010500565A JP2010500565A (ja) | 2010-01-07 |
| JP2010500565A5 true JP2010500565A5 (https=) | 2010-09-24 |
| JP5725711B2 JP5725711B2 (ja) | 2015-05-27 |
Family
ID=39082605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009523844A Active JP5725711B2 (ja) | 2006-08-10 | 2007-08-09 | 癌治療法を有する患者の同定、評価、および治療のための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9500656B2 (https=) |
| EP (1) | EP2046973A4 (https=) |
| JP (1) | JP5725711B2 (https=) |
| AU (1) | AU2007284724B2 (https=) |
| CA (1) | CA2660275A1 (https=) |
| MX (1) | MX2009001489A (https=) |
| WO (1) | WO2008021183A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120004854A1 (en) * | 2008-05-28 | 2012-01-05 | Georgia Tech Research Corporation | Metabolic biomarkers for ovarian cancer and methods of use thereof |
| US20110190157A1 (en) * | 2008-08-15 | 2011-08-04 | The Regents Of The University Of California | Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia |
| US20120149647A1 (en) * | 2009-03-17 | 2012-06-14 | Brody Jonathan R | Methods for Assessing the Efficacy of Gemcitabine or Ara-C Treatment of Cancer Using Human Antigen R Levels |
| US8637481B2 (en) * | 2009-04-17 | 2014-01-28 | University Health Network | Sensitizing agents for cancer therapy, methods of use and methods for the identification thereof |
| EP2419540B1 (en) * | 2009-04-18 | 2017-05-17 | Merck Sharp & Dohme Corp. | Methods and gene expression signature for assessing ras pathway activity |
| US7615353B1 (en) * | 2009-07-06 | 2009-11-10 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
| US20130012409A1 (en) | 2009-10-08 | 2013-01-10 | M Frank | Diagnostic and Prognostic Markers for Cancer |
| WO2011044513A1 (en) * | 2009-10-08 | 2011-04-14 | Wake Forest University Health Sciences | Diagnostic and prognostic markers for cancer |
| EP3178944B1 (en) | 2010-01-11 | 2019-05-15 | Genomic Health, Inc. | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
| US20140322705A1 (en) * | 2010-08-20 | 2014-10-30 | Thomas Jefferson University | Cancer diagnostic and cancer therapeutic |
| MX357429B (es) | 2011-08-11 | 2018-07-09 | Janssen Pharmaceutica Nv | Predictores para el tratamiento del cáncer. |
| GB2523211B (en) | 2012-01-27 | 2020-03-18 | Univ Jefferson | MCT protein inhibitor-related prognostic and therapeutic methods |
| ES2702183T3 (es) * | 2013-03-15 | 2019-02-27 | Mayo Found Medical Education & Res | Identificación y monitorización de inmunoglobulinas monoclonales por masa molecular |
| WO2014172627A1 (en) | 2013-04-19 | 2014-10-23 | Thomas Jefferson University | Caveolin-1 related methods for treating glioblastoma with temozolomide |
| JP2016521979A (ja) | 2013-05-30 | 2016-07-28 | ジェノミック ヘルス， インコーポレイテッド | 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム |
| US20150287143A1 (en) * | 2014-04-03 | 2015-10-08 | John Hancock Life Insurance Company (U.S.A.) | System and method for managing underwriting using a risk order approach |
| WO2015154052A1 (en) | 2014-04-04 | 2015-10-08 | Mayo Foundation For Medical Education And Research | Isotyping immunoglobulins using accurate molecular mass |
| US20170166974A1 (en) * | 2014-05-20 | 2017-06-15 | Erasmus University Medical Center Rotterdam | Method for the treatment of multiple myeloma |
| EP3175242A4 (en) | 2014-07-29 | 2017-12-27 | Mayo Foundation for Medical Education and Research | Quantifying monoclonal antibody therapeutics by lc-ms/ms |
| CN108026164A (zh) | 2015-09-24 | 2018-05-11 | 梅约医学教育与研究基金会 | 通过质谱鉴定免疫球蛋白游离轻链 |
| EP3396573A4 (en) * | 2015-10-26 | 2019-08-28 | Cipherome | METHOD AND SYSTEM FOR SELECTING AN INDIVIDUALLY ADJUSTED MEDICAMENT WITH THE INFORMATION OF THE VARIATIONS OF A GENOMIC NUCLEOTIDE SEQUENCE AND SURVIVAL INFORMATION OF A CANCER PATIENTS |
| AU2017325022B2 (en) | 2016-09-07 | 2022-10-13 | Mayo Foundation For Medical Education And Research | Identification and monitoring of cleaved immunoglobulins by molecular mass |
| EP3635746A4 (en) * | 2017-04-28 | 2021-02-17 | University of Southern California | SYSTEM AND PROCEDURE FOR ESTIMATING SURVIVAL TIME |
| WO2019055634A1 (en) | 2017-09-13 | 2019-03-21 | Mayo Foundation For Medical Education And Research | IDENTIFICATION AND MONITORING OF A MACROPHAGE APOPTOSIS INHIBITOR |
| EP3681907A4 (en) | 2017-09-13 | 2021-07-07 | Mayo Foundation for Medical Education and Research | IDENTIFICATION AND MONITORING OF IMMUNOGLOBULIN J-CHAINS |
| CN110108878A (zh) * | 2019-05-30 | 2019-08-09 | 四川大学华西医院 | Eif2s1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05296999A (ja) * | 1992-04-24 | 1993-11-12 | Amano Pharmaceut Co Ltd | グルココルチコイドの効果判定マーカーとしてのヒトリポコルチンｉ及びその定量法 |
| JP2004248502A (ja) * | 2000-10-05 | 2004-09-09 | Takara Holdings Inc | 癌悪性度の評価方法 |
| CN1647067A (zh) * | 2002-04-04 | 2005-07-27 | 石原产业株式会社 | 数据解析装置及方法 |
| ES2542328T3 (es) * | 2002-12-06 | 2015-08-04 | Millennium Pharmaceuticals, Inc. | Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma |
| US20040191782A1 (en) * | 2003-03-31 | 2004-09-30 | Yixin Wang | Colorectal cancer prognostics |
| US7741035B2 (en) * | 2004-05-21 | 2010-06-22 | Board Of Trustees Of The University Of Arkansas | Use of gene expression profiling to predict survival in cancer patient |
| CA2611728A1 (en) | 2005-06-08 | 2006-12-14 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with cancer therapy |
-
2007
- 2007-08-09 EP EP07836670A patent/EP2046973A4/en not_active Ceased
- 2007-08-09 CA CA002660275A patent/CA2660275A1/en not_active Abandoned
- 2007-08-09 JP JP2009523844A patent/JP5725711B2/ja active Active
- 2007-08-09 WO PCT/US2007/017716 patent/WO2008021183A2/en not_active Ceased
- 2007-08-09 US US11/891,213 patent/US9500656B2/en not_active Expired - Fee Related
- 2007-08-09 MX MX2009001489A patent/MX2009001489A/es active IP Right Grant
- 2007-08-09 AU AU2007284724A patent/AU2007284724B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010500565A5 (https=) | ||
| Bratman et al. | Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab | |
| Zhou et al. | Construction of an immune-related six-lncRNA signature to predict the outcomes, immune cell infiltration, and immunotherapy response in patients with hepatocellular carcinoma | |
| Mordente et al. | Cancer biomarkers discovery and validation: state of the art, problems and future perspectives | |
| Pan et al. | m5C-related lncRNAs predict overall survival of patients and regulate the tumor immune microenvironment in lung adenocarcinoma | |
| Fredsøe et al. | A five‐microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell‐free urine | |
| Che et al. | Evaluation of genetic risk score models in the presence of interaction and linkage disequilibrium | |
| Xu-Welliver et al. | Blood-based biomarkers in lung cancer: prognosis and treatment decisions | |
| Wang et al. | Identification of metastasis-related genes for predicting prostate cancer diagnosis, metastasis and immunotherapy drug candidates using machine learning approaches | |
| Schena et al. | DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients | |
| JP2017503527A5 (https=) | ||
| WO2016025958A1 (en) | Methods and materials for assessing homologous recombination deficiency | |
| JP2008544223A5 (https=) | ||
| Kim et al. | Clinicopathologic, molecular, and prognostic implications of the loss of EPCAM expression in colorectal carcinoma | |
| ES2882875T3 (es) | Método de pronóstico y predicción de la recurrencia del cáncer de mama, marcadores empleados en el mismo y kit del mismo | |
| Kim et al. | Upgrading of Gleason score and prostate volume: a clinicopathological analysis. | |
| WO2011133949A3 (en) | Genetic risk analysis in reward deficiency syndrome | |
| Fredsøe et al. | Independent validation of a diagnostic noninvasive 3-MicroRNA ratio model (uCaP) for prostate cancer in cell-free urine | |
| Wilson et al. | Breast cancer histopathology is predictive of low‐risk Oncotype Dx recurrence score | |
| ES2914727T3 (es) | Algoritmos y métodos para evaluar los criterios clínicos tardíos en el cáncer de próstata | |
| Vaezi et al. | ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer | |
| Nam et al. | Identification of a novel MicroRNA panel associated with metastasis following radical prostatectomy for prostate cancer | |
| Ru et al. | Biomarkers for prognosis and treatment selection in advanced bladder cancer patients | |
| Liu et al. | Prognostic significance and immunological role of FBXO5 in human cancers: a systematic pan-cancer analysis | |
| Hauser et al. | Cell-free serum DNA in patients with bladder cancer: results of a prospective multicenter study |